Article Versions Notes

Liu R, Shinriki S, Maeshiro M, Hirayama M, Jono H, Yoshida R, Nakayama H, Matsui H. The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma. Cancers. 2022; 14(1):173. https://doi.org/10.3390/cancers14010173

Liu, Rin, Satoru Shinriki, Manabu Maeshiro, Mayumi Hirayama, Hirofumi Jono, Ryoji Yoshida, Hideki Nakayama, and Hirotaka Matsui. 2022. "The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma" Cancers 14, no. 1: 173. https://doi.org/10.3390/cancers14010173

Liu, R., Shinriki, S., Maeshiro, M., Hirayama, M., Jono, H., Yoshida, R., Nakayama, H., & Matsui, H. (2022). The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma. Cancers, 14(1), 173. https://doi.org/10.3390/cancers14010173